PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC
- Written by PR Newswire
 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
